GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
중증 코로나19 폐렴에서 렌질루맙으로 GM-CSF 중화: 사례-코호트 연구
Multicenter Study
[키워드] Absolute lymphocyte count
acute respiratory distress
adverse event
age
Analysis
C-reactive protein
Characteristics
clinical
clinical endpoint
Clinical improvement
clinical outcomes
Cohort
cohort of patient
COVID-19
COVID-19 patient
death
defined
disease severity
dose
Efficacy and safety
faster
GM-CSF
greater
hospital discharge
Hospitalized
Inflammatory
Inflammatory marker
intravenously
Laboratory
marker
median
myeloid cell
neutralization
outcome
outcomes
oxygen
Oxygenation
Patient
patients treated
patients with COVID-19
placebo-controlled clinical trial
Pneumonia
proportion
Randomized
reduced
reduction in
reductions in
risk factor
Safe
severe coronavirus disease
Severe COVID-19 pneumonia
severe pneumonia
Sex
Significant
significantly
significantly shorter
syndrome
treated
Treatment
treatment-emergent adverse event
untreated patients
were recorded
[DOI] 10.1016/j.mayocp.2020.08.038 PMC 바로가기 [Article Type] Multicenter Study
[DOI] 10.1016/j.mayocp.2020.08.038 PMC 바로가기 [Article Type] Multicenter Study